NorthWest Biotherapeutics Inc (NWBO)

[Ready4bluesky]

Although DCVAX may soon be considered horse and buggy technology, NWBO is one of several companies that helped pioneer the DC vaccine approach over the last decade. Regardless of the outcome, these clinical trials will provide very meaningful scientific research and data that will help future scientists and biotechs develop much more effective treatment options in the fight against cancer. LP, NWBO employees, and investors should take a lot of pride in the sacrifices they have made to further this research. It is very possible we will see major breakthroughs in cancer treatment in the next couple of decades.

One last thought from an investment perspective. Since most small biotechs eventually fail, it is prudent to invest accordingly. Woodford has set a good example with his portfolio allocation of less than 1% to NWBO. If things go south, the damage to the portfolio will be minimal. This is a responsible approach that should not be ignored.